Results 191 to 200 of about 2,826,213 (281)

Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond

open access: yesObesity Reviews, EarlyView.
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed   +19 more
wiley   +1 more source

Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)

open access: yesObesity Reviews, EarlyView.
Challenges and evidence in obesity guidelines. ABSTRACT Obesity remains a global health crisis characterized by substantial heterogeneity in diagnosis, management, and policy implementation. Although numerous national and international clinical practice guidelines have been published over the past decade, their translation into evidence‐based and ...
Rosero‐Revelo Ricardo   +13 more
wiley   +1 more source

Leptin Resistance

open access: yesJournal of Korean Endocrine Society, 2007
openaire   +1 more source

Epigenomic Cascades Across Organs in Metabolic Dysfunction–Associated Steatotic Liver Disease: New Therapeutic Horizons

open access: yesObesity Reviews, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disorder worldwide, affecting approximately one‐third of the population and increasing the risk of severe hepatic and cardiovascular complications.
Shurui Yang   +4 more
wiley   +1 more source

Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan

open access: yesObesity Reviews, EarlyView.
ABSTRACT Obesity arises from intertwined and reciprocal diet‐microbiome‐host pathways that reshape energy balance, insulin sensitivity, and inflammation. This review synthesizes mechanistic links between microbial functions and metabolic control, charts lifestyle‐related lifecourse dynamics from birth to older age, examines how GLP‐1‐based therapies ...
Ioanna Panagiota Kalafati   +12 more
wiley   +1 more source

Toward “Obesityomics”: Domain‐Specific Omics in Precision Obesity Medicine with a Brief AI Perspective

open access: yesObesity Reviews, EarlyView.
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra   +13 more
wiley   +1 more source

Investigating Overweight and Obesity Risk in Shift Workers Using Omics Technologies

open access: yesObesity Reviews, EarlyView.
ABSTRACT Night shift workers are at higher risk of developing overweight and obesity. The disruption of the physiological circadian rhythm leads to metabolic alterations, such as decreased insulin sensitivity, increased adipogenesis, and inflammation, with effects on their health and leading, among other diseases, to obesity.
Katrin Scionti   +3 more
wiley   +1 more source

Inflammatory mediator contributes to leptin resistance and obesity in craniopharyngioma. [PDF]

open access: yesFASEB J
Xiao Y   +9 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment

open access: yesObesity Reviews, EarlyView.
ABSTRACT Obesity is a well‐established risk factor for numerous cancers, with body habitus, especially central adiposity, contributing to increased cancer incidence and worse prognosis. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed to treat Type 2 diabetes, have rapidly gained prominence as powerful anti‐obesity agents due ...
Lorne J. Hofseth   +6 more
wiley   +1 more source

Skeletal glucocorticoid signalling determines leptin resistance and obesity in aging mice. [PDF]

open access: yesMol Metab, 2020
Henneicke H   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy